Cargando…

Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

BACKGROUND: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Daniel E., Hellkamp, Anne S., Yuan, Zhong, Lokhnygina, Yuliya, Patel, Manesh R., Piccini, Jonathan P., Hankey, Graeme J., Breithardt, Günter, Halperin, Jonathan L., Becker, Richard C., Hacke, Werner, Nessel, Christopher C., Mahaffey, Kenneth W., Fox, Keith A. A., Califf, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392426/
https://www.ncbi.nlm.nih.gov/pubmed/25736441
http://dx.doi.org/10.1161/JAHA.114.001349
_version_ 1782365977228345344
author Singer, Daniel E.
Hellkamp, Anne S.
Yuan, Zhong
Lokhnygina, Yuliya
Patel, Manesh R.
Piccini, Jonathan P.
Hankey, Graeme J.
Breithardt, Günter
Halperin, Jonathan L.
Becker, Richard C.
Hacke, Werner
Nessel, Christopher C.
Mahaffey, Kenneth W.
Fox, Keith A. A.
Califf, Robert M.
author_facet Singer, Daniel E.
Hellkamp, Anne S.
Yuan, Zhong
Lokhnygina, Yuliya
Patel, Manesh R.
Piccini, Jonathan P.
Hankey, Graeme J.
Breithardt, Günter
Halperin, Jonathan L.
Becker, Richard C.
Hacke, Werner
Nessel, Christopher C.
Mahaffey, Kenneth W.
Fox, Keith A. A.
Califf, Robert M.
author_sort Singer, Daniel E.
collection PubMed
description BACKGROUND: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range (iTTR) of the international normalized ratio (INR), were associated with longer inter‐INR test intervals. The standard Rosendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow‐up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial. METHODS AND RESULTS: We used an INR imputation method that accounts for dose change. We compared group mean iTTR values between our dose change–based method with the standard Rosendaal method and determined that the differences between approaches depended on the balance of dose changes that produced in‐range INRs (“corrections”) versus INRs that were out of range in the opposite direction (“overshoots”). In ROCKET AF, the overall mean iTTR of 55.2% (Rosendaal) increased up to 3.1% by using the dose change–based approach, depending on assumptions. However, large inter‐regional differences in anticoagulation control persisted. CONCLUSIONS: TTR, the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow‐up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter‐regional differences previously reported. CLINICAL TRIAL REGISTRATION: URL: ClinicalTrials.gov. Unique identifier: NCT00403767.
format Online
Article
Text
id pubmed-4392426
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43924262015-04-14 Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial Singer, Daniel E. Hellkamp, Anne S. Yuan, Zhong Lokhnygina, Yuliya Patel, Manesh R. Piccini, Jonathan P. Hankey, Graeme J. Breithardt, Günter Halperin, Jonathan L. Becker, Richard C. Hacke, Werner Nessel, Christopher C. Mahaffey, Kenneth W. Fox, Keith A. A. Califf, Robert M. J Am Heart Assoc Original Research BACKGROUND: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range (iTTR) of the international normalized ratio (INR), were associated with longer inter‐INR test intervals. The standard Rosendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow‐up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial. METHODS AND RESULTS: We used an INR imputation method that accounts for dose change. We compared group mean iTTR values between our dose change–based method with the standard Rosendaal method and determined that the differences between approaches depended on the balance of dose changes that produced in‐range INRs (“corrections”) versus INRs that were out of range in the opposite direction (“overshoots”). In ROCKET AF, the overall mean iTTR of 55.2% (Rosendaal) increased up to 3.1% by using the dose change–based approach, depending on assumptions. However, large inter‐regional differences in anticoagulation control persisted. CONCLUSIONS: TTR, the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow‐up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter‐regional differences previously reported. CLINICAL TRIAL REGISTRATION: URL: ClinicalTrials.gov. Unique identifier: NCT00403767. Blackwell Publishing Ltd 2015-03-03 /pmc/articles/PMC4392426/ /pubmed/25736441 http://dx.doi.org/10.1161/JAHA.114.001349 Text en © 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Singer, Daniel E.
Hellkamp, Anne S.
Yuan, Zhong
Lokhnygina, Yuliya
Patel, Manesh R.
Piccini, Jonathan P.
Hankey, Graeme J.
Breithardt, Günter
Halperin, Jonathan L.
Becker, Richard C.
Hacke, Werner
Nessel, Christopher C.
Mahaffey, Kenneth W.
Fox, Keith A. A.
Califf, Robert M.
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title_full Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title_fullStr Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title_full_unstemmed Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title_short Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
title_sort alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the rocket af trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392426/
https://www.ncbi.nlm.nih.gov/pubmed/25736441
http://dx.doi.org/10.1161/JAHA.114.001349
work_keys_str_mv AT singerdaniele alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT hellkampannes alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT yuanzhong alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT lokhnyginayuliya alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT patelmaneshr alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT piccinijonathanp alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT hankeygraemej alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT breithardtgunter alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT halperinjonathanl alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT beckerrichardc alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT hackewerner alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT nesselchristopherc alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT mahaffeykennethw alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT foxkeithaa alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT califfrobertm alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial
AT alternativecalculationsofindividualpatienttimeintherapeuticrangewhiletakingwarfarinresultsfromtherocketaftrial